Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) just unveiled an update.
Hansoh Pharmaceutical Group reported a 14.3% increase in revenue for the first half of 2025, driven by innovative drugs and collaborative products, which accounted for 82.7% of total revenue. Key achievements include FDA Breakthrough Therapy Designation for a B7-H3-targeted ADC and multiple drug approvals by the NMPA, enhancing the company’s market position and growth prospects.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$34.83 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a leading innovation-driven pharmaceutical enterprise in China, focusing on major disease therapeutic areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmunity. The company has launched seven innovative drugs in the PRC, forming a rich product pipeline.
Average Trading Volume: 11,591,839
Technical Sentiment Signal: Buy
Current Market Cap: HK$221.8B
For an in-depth examination of 3692 stock, go to TipRanks’ Overview page.